Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report

Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Montoro, José Ignacio, Pinzón-Martín, José Luis, Damas-Fuentes, Miguel, Fernández-Valero, Andrea, Tinahones, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046779/
https://www.ncbi.nlm.nih.gov/pubmed/35498407
http://dx.doi.org/10.3389/fendo.2022.838887
_version_ 1784695586315829248
author Martínez-Montoro, José Ignacio
Pinzón-Martín, José Luis
Damas-Fuentes, Miguel
Fernández-Valero, Andrea
Tinahones, Francisco J.
author_facet Martínez-Montoro, José Ignacio
Pinzón-Martín, José Luis
Damas-Fuentes, Miguel
Fernández-Valero, Andrea
Tinahones, Francisco J.
author_sort Martínez-Montoro, José Ignacio
collection PubMed
description Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.
format Online
Article
Text
id pubmed-9046779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90467792022-04-29 Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report Martínez-Montoro, José Ignacio Pinzón-Martín, José Luis Damas-Fuentes, Miguel Fernández-Valero, Andrea Tinahones, Francisco J. Front Endocrinol (Lausanne) Endocrinology Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome. Frontiers Media S.A. 2022-04-14 /pmc/articles/PMC9046779/ /pubmed/35498407 http://dx.doi.org/10.3389/fendo.2022.838887 Text en Copyright © 2022 Martínez-Montoro, Pinzón-Martín, Damas-Fuentes, Fernández-Valero and Tinahones https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Martínez-Montoro, José Ignacio
Pinzón-Martín, José Luis
Damas-Fuentes, Miguel
Fernández-Valero, Andrea
Tinahones, Francisco J.
Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
title Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
title_full Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
title_fullStr Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
title_full_unstemmed Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
title_short Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
title_sort combination therapy with semaglutide and dapagliflozin as an effective approach for the management of type a insulin resistance syndrome: a case report
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046779/
https://www.ncbi.nlm.nih.gov/pubmed/35498407
http://dx.doi.org/10.3389/fendo.2022.838887
work_keys_str_mv AT martinezmontorojoseignacio combinationtherapywithsemaglutideanddapagliflozinasaneffectiveapproachforthemanagementoftypeainsulinresistancesyndromeacasereport
AT pinzonmartinjoseluis combinationtherapywithsemaglutideanddapagliflozinasaneffectiveapproachforthemanagementoftypeainsulinresistancesyndromeacasereport
AT damasfuentesmiguel combinationtherapywithsemaglutideanddapagliflozinasaneffectiveapproachforthemanagementoftypeainsulinresistancesyndromeacasereport
AT fernandezvaleroandrea combinationtherapywithsemaglutideanddapagliflozinasaneffectiveapproachforthemanagementoftypeainsulinresistancesyndromeacasereport
AT tinahonesfranciscoj combinationtherapywithsemaglutideanddapagliflozinasaneffectiveapproachforthemanagementoftypeainsulinresistancesyndromeacasereport

Ejemplares similares